Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Gilla KaplanDirector | Tyra BiosciencesTYRA | Open-market sale | 03/25 | 03/27 | 14,295 sh | $36.97 | $528,486.15 | −33.6% |
Tyra BiosciencesTYRA | Open-market sale10b5-1 plan | 02/12 | 02/13 | 8,000 sh2 trades | $32.87avg. | $262,980.64 | −5.2% | |
Tyra BiosciencesTYRA | Open-market sale10b5-1 plan | 01/12 | 01/20 | 8,000 sh2 trades | $28.52avg. | $228,170.88 | −4.9% | |
Robert J. MoreDirector | Tyra BiosciencesTYRA | Open-market sale10b5-1 plan | 25/12/19 | 25/12/19 | 10,000 sh | $25.00 | $250,000 | −0.3% |
Daniel BensenChief Discovery Officer | Tyra BiosciencesTYRA | Open-market sale10b5-1 plan | 25/12/12 | 25/12/16 | 8,000 sh | $22.64 | $181,120 | −4.7% |
Robert J. MoreDirector | Tyra BiosciencesTYRA | Open-market sale10b5-1 plan | 25/11/21 | 25/11/25 | 246,871 sh | $20.25 | $4,999,137.75 | −6.1% |
Tyra BiosciencesTYRA | Open-market sale10b5-1 plan | 25/11/18–25/11/19 | 25/11/19 | 125,589 sh2 trades | $16.17avg. | $2,030,704.23 | −42.3% | |
Tyra BiosciencesTYRA | Open-market sale10b5-1 plan | 25/11/13–25/11/17 | 25/11/17 | 131,411 sh4 trades | $16.04avg. | $2,108,428.48 | −30.7% | |
Tyra BiosciencesTYRA | Open-market sale | 25/06/17–25/06/18 | 25/06/20 | 9,578 sh2 trades | $9.78avg. | $93,678.54 | −25.3% | |
Tyra BiosciencesTYRA | Open-market sale | 25/06/12–25/06/16 | 25/06/16 | 51,814 sh3 trades | $10.32avg. | $534,679.32 | −57.8% | |
Tyra BiosciencesTYRA | Open-market buy | 25/06/12–25/06/16 | 25/06/16 | 163,287 sh3 trades | $10.19avg. | $1,664,700.49 | +1.6% | |
RA Capital Healthcare FundDirector | Tyra BiosciencesTYRA | Open-market buy | 25/06/09 | 25/06/11 | 186,850 sh | $10.19 | $1,904,001.5 | +1.9% |
Tyra BiosciencesTYRA | Open-market buy | 25/06/04–25/06/05 | 25/06/06 | 1,211,198 sh2 trades | $9.70avg. | $11,751,303.68 | +13.9% | |
Tyra BiosciencesTYRA | Open-market sale | 25/02/05 | 25/02/07 | 5,401 sh2 trades | $13.76avg. | $74,317.76 | −1.2% | |
Nina S. KjellsonDirector | Tyra BiosciencesTYRA | Open-market sale | 25/01/23 | 25/01/27 | 4,825 sh | $16.26 | $78,454.5 | −0.1% |
Tyra BiosciencesTYRA | Open-market sale | 25/01/16–25/01/21 | 25/01/21 | 25,041 sh5 trades | $16.36avg. | $409,656.99 | −0.7% | |
Tyra BiosciencesTYRA | Open-market sale | 24/11/25 | 24/11/26 | 5,272 sh2 trades | $16.84avg. | $88,780.48 | −1.2% | |
RA Capital Healthcare FundDirector | Tyra BiosciencesTYRA | Open-market buy | 24/11/08 | 24/11/13 | 1,220,681 sh | $16.25 | $19,836,066.25 | +16.3% |
Tyra BiosciencesTYRA | Open-market sale | 24/11/06–24/11/07 | 24/11/08 | 74,582 sh4 trades | $17.22avg. | $1,284,411.5 | −14.2% | |
Tyra BiosciencesTYRA | Open-market sale | 24/11/04–24/11/05 | 24/11/06 | 11,569 sh4 trades | $16.79avg. | $194,270.37 | −2.5% |